{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:09:21Z","timestamp":1792372161591,"version":"4.4.0"},"reference-count":53,"publisher":"Tottori University Faculty of Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Yonago Acta Med."],"published-print":{"date-parts":[[2025]]},"DOI":"10.33160\/yam.2025.08.001","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T22:07:51Z","timestamp":1752703671000},"page":"169-179","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies"],"prefix":"10.33160","volume":"68","author":[{"given":"Koji","family":"Kawamura","sequence":"first","affiliation":[{"name":"Division of Hematology and Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-0853, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18656","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091-101. PMID:21105791, DOI:10.1056\/NEJMoa1004383","DOI":"10.1056\/NEJMoa1004383"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003\u20132007 Versus 2013\u20132017 Cohorts. Ann Intern Med. 2020;172:229-39. PMID:31958813, DOI:10.7326\/M19-2936","DOI":"10.7326\/M19-2936"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia\/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Bone Marrow Transplant. 2013;48:529-36. PMID:22964595, DOI:10.1038\/bmt.2012.172","DOI":"10.1038\/bmt.2012.172"},{"key":"4","unstructured":"4. Hematopoietic Cell Transplantation and Cellular Therapy in Japan. Annual Report of Nationwide Survey 2024 [Internet]. Nagakute: The Japanese Data Center for Hematopoietic Cell Transplantation; [cited 2025 May 15]. Available from: https:\/\/www.jdchct.or.jp\/data\/report\/2024\/."},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156-64. PMID:28674027, DOI:10.1182\/blood-2017-03-772368","DOI":"10.1182\/blood-2017-03-772368"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, et al. Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR. Transplant Cell Ther. 2025. [Online ahead of print]DOI:10.1016\/j.jtct.2025.05.014","DOI":"10.1016\/j.jtct.2025.05.014"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, et al. Allogeneic Stem Cell Transplantation for Patients Age \u2265 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biol Blood Marrow Transplant. 2017;23:44-52. PMID:27720995, DOI:10.1016\/j.bbmt.2016.09.027","DOI":"10.1016\/j.bbmt.2016.09.027"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Deeg HJ, Steuten LM. Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics. JAMA Oncol. 2015;1:571-2. PMID:26181003, DOI:10.1001\/jamaoncol.2015.1084","DOI":"10.1001\/jamaoncol.2015.1084"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Thibaud V, Piron A, Bron D. Frailty score of older patients with haematological malignancies: unsuspected role of mild cognitive impairment. Br J Haematol. 2020;190:144-8. PMID:32141067, DOI:10.1111\/bjh.16469","DOI":"10.1111\/bjh.16469"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Crimmin J, Fulop T, Battisti NML. Biological aspects of aging that influence response to anticancer treatments. Curr Opin Support Palliat Care. 2021;15:29-38. PMID:33399393, DOI:10.1097\/SPC.0000000000000536","DOI":"10.1097\/SPC.0000000000000536"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70-87. PMID:31101526, DOI:10.1016\/j.blre.2019.04.005","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1-15. PMID:30314642, DOI:10.1016\/j.blre.2018.09.001","DOI":"10.1016\/j.blre.2018.09.001"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, et al. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023;98:1383-93. PMID:37334870, DOI:10.1002\/ajh.26997","DOI":"10.1002\/ajh.26997"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, et al. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023;7:3573-81. PMID:37104058, DOI:10.1182\/bloodadvances.2022009632","DOI":"10.1182\/bloodadvances.2022009632"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematology (Am Soc Hematol Educ Program). 2021;2021:254-63. PMID:34889392, DOI:10.1182\/hematology.2021000257","DOI":"10.1182\/hematology.2021000257"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Liu MA, Hshieh T, Condron N, Wadleigh M, Abel GA, Driver JA. Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies. Br J Cancer. 2016;115:858-61. PMID:27552440, DOI:10.1038\/bjc.2016.260","DOI":"10.1038\/bjc.2016.260"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Saraceni F, Labopin M, Forcade E, Kr\u00f6ger N, Soci\u00e9 G, Niittyvuopio R, et al. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Med. 2021;10:23-33. PMID:33242374, DOI:10.1002\/cam4.3593","DOI":"10.1002\/cam4.3593"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Yamasaki S, Mizuno S, Iwasaki M, Seo S, Uchida N, Shigesaburo M, et al. Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics. Ann Hematol. 2023;102:1549-59. PMID:37126115, DOI:10.1007\/s00277-023-05243-0","DOI":"10.1007\/s00277-023-05243-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-9. PMID:15994282, DOI:10.1182\/blood-2005-05-2004","DOI":"10.1182\/blood-2005-05-2004"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249-56. PMID:25154831, DOI:10.1200\/JCO.2013.53.8157","DOI":"10.1200\/JCO.2013.53.8157"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Brown AS, Brummel-Smith K, Burgess L, D\u2019Agostino RB, Goldschmidt JW, Halter JB, et al. National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. J Am Geriatr Soc. 1988;36:342-7. PMID:3280648, DOI:10.1111\/j.1532-5415.1988.tb02362.x","DOI":"10.1111\/j.1532-5415.1988.tb02362.x"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, et al. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020;26:189-96. PMID:31493541, DOI:10.1016\/j.bbmt.2019.08.022","DOI":"10.1016\/j.bbmt.2019.08.022"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4:2810-20. PMID:32574365, DOI:10.1182\/bloodadvances.2020001719","DOI":"10.1182\/bloodadvances.2020001719"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Lin RJ, Elko TA, Devlin SM, Shahrokni A, Jakubowski AA, Dahi PB, et al. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplant. 2020;55:157-64. PMID:31471572, DOI:10.1038\/s41409-019-0654-6","DOI":"10.1038\/s41409-019-0654-6"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Holmes HM, Des Bordes JKA, Kebriaei P, Yennu S, Champlin RE, Giralt S, et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. 2014;5:422-30. PMID:24835889, DOI:10.1016\/j.jgo.2014.04.004","DOI":"10.1016\/j.jgo.2014.04.004"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Aydin S, Passera R, Cerrano M, Giai V, D\u2019Ardia S, Iovino G, et al. Combining the HCT-CI, G8, and AML-Score for Fitness Evaluation of Elderly Patients with Acute Myeloid Leukemia: A Single Center Analysis. Cancers (Basel). 2023;15:1002. PMID:36831347, DOI:10.3390\/cancers15041002","DOI":"10.3390\/cancers15041002"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-33. PMID:19896087, DOI:10.1016\/j.bbmt.2009.07.004","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367-9. PMID:19203728, DOI:10.1016\/j.bbmt.2008.12.497","DOI":"10.1016\/j.bbmt.2008.12.497"},{"key":"29","unstructured":"29. The Japan Society for Hematopoietic Cell Transplantation (JSHCT). Hematopoietic Cell Transplantation Guidelines: Conditioning Regimens (Version 2). 2020. Japanese."},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Kawamura K, Kako S, Mizuta S, Ishiyama K, Aoki J, Yano S, et al. Comparison of Conditioning with Fludarabine\/Busulfan and Fludarabine\/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. Biol Blood Marrow Transplant. 2017;23:2079-87. PMID:28890406, DOI:10.1016\/j.bbmt.2017.09.003","DOI":"10.1016\/j.bbmt.2017.09.003"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Yanada M, Yamasaki S, Konuma T, Mizuno S, Uchida N, Onai D, et al. Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. Int J Hematol. 2023;117:398-408. PMID:36335534, DOI:10.1007\/s12185-022-03486-7","DOI":"10.1007\/s12185-022-03486-7"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Shinohara A, Shindo M, Nakano N, Sakaida E, Uchida N, Fukushima K, et al. Increased Non\u2010Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan\u2010Based Regimen. Eur J Haematol. 2025;114:852-63. PMID:39834012, DOI:10.1111\/ejh.14374","DOI":"10.1111\/ejh.14374"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, et al. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018;24:1828-35. PMID:29753158, DOI:10.1016\/j.bbmt.2018.04.029","DOI":"10.1016\/j.bbmt.2018.04.029"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339-48. PMID:25054717, DOI:10.1056\/NEJMsa1311707","DOI":"10.1056\/NEJMsa1311707"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Kawamura K. Effect of antithymocyte globulin on HLA-mismatched unrelated transplantation. Int J Hematol. 2019;110:22-9. PMID:30680666, DOI:10.1007\/s12185-019-02597-y","DOI":"10.1007\/s12185-019-02597-y"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Timofeeva OA, Philogene MC, Zhang QJ. Current donor selection strategies for allogeneic hematopoietic cell transplantation. Hum Immunol. 2022;83:674-86. PMID:36038413, DOI:10.1016\/j.humimm.2022.08.007","DOI":"10.1016\/j.humimm.2022.08.007"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Kr\u00f6ger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, et al.; MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia. 2013;27:604-9. PMID:22821073, DOI:10.1038\/leu.2012.210","DOI":"10.1038\/leu.2012.210"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Guru Murthy GS, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M, et al. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022;8:404-11. PMID:35024768, DOI:10.1001\/jamaoncol.2021.6846","DOI":"10.1001\/jamaoncol.2021.6846"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. .Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM, et al. Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis. Transplant Cell Ther. 2024; 30(7):687.e1-687.e13. PMID:38703824, DOI:10.1016\/j.jtct.2024.05.001","DOI":"10.1016\/j.jtct.2024.05.001"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641-50. PMID:18489989, DOI:10.1016\/j.bbmt.2008.03.005","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, et al. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019;3:2581-5. PMID:31484635, DOI:10.1182\/bloodadvances.2019000614","DOI":"10.1182\/bloodadvances.2019000614"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Sugita J. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol. 2019;110:30-8. PMID:31104211, DOI:10.1007\/s12185-019-02660-8","DOI":"10.1007\/s12185-019-02660-8"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43. Kasamon YL, Bola\u00f1os-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, et al. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015;33:3152-61. PMID:26261255, DOI:10.1200\/JCO.2014.60.4777","DOI":"10.1200\/JCO.2014.60.4777"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44. Imus PH, Tsai HL, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, et al. Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019;3:2608-16. PMID:31492679, DOI:10.1182\/bloodadvances.2019000155","DOI":"10.1182\/bloodadvances.2019000155"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11:55. PMID:29661208, DOI:10.1186\/s13045-018-0598-0","DOI":"10.1186\/s13045-018-0598-0"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46. Konuma T, Tsukada N, Kanda J, Uchida N, Ohno Y, Miyakoshi S, et al.; Donor\/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. Am J Hematol. 2016;91:E284-92. PMID:26910296, DOI:10.1002\/ajh.24340","DOI":"10.1002\/ajh.24340"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)\/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33:4167-75. PMID:26527780, DOI:10.1200\/JCO.2015.62.7273","DOI":"10.1200\/JCO.2015.62.7273"},{"key":"48","doi-asserted-by":"publisher","unstructured":"48. Chalandon Y, Devillier R, Boumendil A, Nguyen S, Bulabois CE, Ceballos P, et al. Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et Th\u00e9rapie Cellulaire ( SFGM \u2010 TC ). Am J Hematol. 2025;100:1173-84. PMID:40326583, DOI:10.1002\/ajh.27701","DOI":"10.1002\/ajh.27701"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49. Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60\u201375 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33:2599-609. PMID:31073153, DOI:10.1038\/s41375-019-0477-x","DOI":"10.1038\/s41375-019-0477-x"},{"key":"50","doi-asserted-by":"publisher","unstructured":"50. Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021;39:3328-39. PMID:34106753, DOI:10.1200\/JCO.20.03380","DOI":"10.1200\/JCO.20.03380"},{"key":"51","doi-asserted-by":"publisher","unstructured":"51. Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, et al. Health\u2010related quality of life in reduced\u2010intensity hematopoietic cell transplantation based on donor availability in patients aged 50\u201375 with advanced myelodysplastic syndrome: BMT CTN 1102. Am J Hematol. 2023;98:229-50. PMID:36251401, DOI:10.1002\/ajh.26768","DOI":"10.1002\/ajh.26768"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52. Saber W, Bansal A, Li L, Scott BL, Sangaralingham LR, Thao V, et al. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: analysis of BMT CTN 1102. JCO Oncol Pract. 2024;20:572-80. PMID:38261970, DOI:10.1200\/OP.23.00413","DOI":"10.1200\/OP.23.00413"},{"key":"53","doi-asserted-by":"publisher","unstructured":"53. Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, et al. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study. Haematologica. 2025;110:68-77. 9 PMID:39113672, DOI:10.3324\/haematol.2024.285879","DOI":"10.3324\/haematol.2024.285879"}],"container-title":["Yonago Acta Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/68\/3\/68_2025.08.001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T04:43:35Z","timestamp":1755924215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/68\/3\/68_2025.08.001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.33160\/yam.2025.08.001","relation":{},"ISSN":["1346-8049"],"issn-type":[{"value":"1346-8049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2025.08.001"}}